World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
64576
World Ranking
3434
National Ranking
342

Overview

Stan B. Kaye is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research broadly spans the field of Medicine, with specific focus on subfields such as Pulmonary and Respiratory Medicine, Reproductive Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, and Epidemiology.

The main topics covered in their work include ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, radiomics and machine learning in medical imaging, lung cancer diagnosis and treatment, immune cell function and interaction, advanced X-ray and CT imaging, and lung cancer treatments and mutations.

Recent publications by Stan B. Kaye include the following:

  • Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer, 2021, EMBO Molecular Medicine
  • Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation, 2020, Lung Cancer
  • A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules, 2022, EBioMedicine
  • Faecal immunochemical testing in symptomatic patients to prioritize investigation: diagnostic accuracy from NICE FIT Study, 2021, British journal of surgery
  • Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial, 2021, ESMO Open

Stan B. Kaye has frequently published in a range of venues including EMBO Molecular Medicine, EBioMedicine, Lung Cancer, British journal of surgery, and ESMO Open.

Collaboration has been a notable aspect of their work, with frequent co-authors including Michał Marek Hoppe, Patrick Jaynes, Joanna D. Wardyn, Tuan Zea Tan, and Stefanus Lie.

Best Publications

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Carboplatin or cisplatin

    A.H. Calvert;A. Horwich;E.S. Newlands;R. Begent

  • International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

    GM Mead;SP Stenning;P Cook;SD Fossa

  • Rethinking ovarian cancer: recommendations for improving outcomes

    Sebastian Vaughan;Jermaine I. Coward;Robert C. Bast;Andy Berchuck

  • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau

  • Ovarian cancer: strategies for overcoming resistance to chemotherapy

    Roshan Agarwal;Stan B. Kaye

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

    Martine J. Piccart;Kamma Bertelsen;Keith James;Jim Cassidy

  • Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

    Paul A. Vasey;Stan B. Kaye;Rosemary Morrison;Chris Twelves

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud

  • Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

    J Baselga;D Rischin;M Ranson;H Calvert

  • Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    T Eisen;T Ahmad;K T Flaherty;M Gore

  • Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

    Paul Vasey;Gordon C Jayson;Alan Gordon;Hani Gabra

  • Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

    Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker

  • Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid

  • Beyond chemotherapy: targeted therapies in ovarian cancer

    Timothy A. Yap;Craig P. Carden;Craig P. Carden;Stan B. Kaye;Stan B. Kaye

  • Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

    J. Nemunaitis;F. Khuri;I. Ganly;J. Arseneau

  • "BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations

    David S.P. Tan;Christian Rothermundt;Karen Thomas;Elizabeth Bancroft

  • Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

    Stan B. Kaye;Jan Lubinski;Ursula Matulonis;Joo Ern Ang

Frequent Co-Authors

Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Martin Gore
Martin Gore Royal Marsden NHS Foundation Trust
Ian Judson
Ian Judson Institute of Cancer Research
David J. Kerr
David J. Kerr University of Oxford
Paul Workman
Paul Workman Institute of Cancer Research
Gerhardt Attard
Gerhardt Attard University College London
Jim Cassidy
Jim Cassidy University of Glasgow
Jan H.M. Schellens
Jan H.M. Schellens Utrecht University
Alan Ashworth
Alan Ashworth University of California, San Francisco
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexible or alternative ways to begin, several online degree options are available. For those already working as registered nurses, pursuing the cheapest rn to bsn online programs can be an affordable step toward career advancement, higher salaries, and broader clinical responsibilities.

Non-nurses or individuals with a bachelor’s degree in another field can explore direct entry msn online programs. These programs offer an accelerated route into advanced practice nursing and can help you pivot into healthcare without starting from scratch.

For a streamlined path into nursing, some of the adn programs provide accessible entry-level training and can often be completed more quickly than four-year degrees.

Additionally, for those interested in the administrative side of healthcare, certified billing and coding roles are in high demand. Many students ask, can you get financial aid for medical billing and coding? The answer is yes—there are accredited online options with financial support to help you get started.

Best Scientists Citing Stan B. Kaye

Trending Scientists

Recently Published Articles